Suman Iva, Šimić Lidija, Čanadi Jurešić Gordana, Buljević Sunčica, Klepac Damir, Domitrović Robert
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Point-of-Care Laboratory, Emergency Department Sušak, Clinical Hospital Center Rijeka, Rijeka, Croatia.
Cell Death Discov. 2024 Feb 24;10(1):98. doi: 10.1038/s41420-024-01872-0.
AKI induced by CP chemotherapy remains an obstacle during patient treatments. Extracellular signal-regulated protein kinases 1/2 (ERK), key participants in CP-induced nephrotoxicity, are suggested to be involved in the regulation of mitophagy, autophagy, and apoptosis. Human renal proximal tubular cells (HK-2) and BALB/cN mice were used to determine the role of ERK in CP-induced AKI. We found that active ERK is involved in cell viability reduction during apoptotic events but exerts a protective role in the early stages of treatment. Activation of ERK acts as a maintainer of the mitochondrial population and is implicated in mitophagy initiation but has no significant role in its conduction. In the late stages of CP treatment when ATP is deprived, general autophagy that requires ERK activation is initiated as a response, in addition to apoptosis activation. Furthermore, activation of ERK is responsible for the decrease in reserve respiratory capacity and controls glycolysis regulation during CP treatment. Additionally, we found that ERK activation is also required for the induction of NOXA gene and protein expression as well as FoxO3a nuclear translocation, but not for the regular ERK-induced phosphorylation of FoxO3a on Ser294. In summary, this study gives detailed insight into the involvement of ERK activation and its impact on key cellular processes at different time points during CP-induced kidney injury. Inhibitors of ERK activation, including Mirdametinib, are important in the development of new therapeutic strategies for the treatment of AKI in patients receiving CP chemotherapy.
CP化疗诱导的急性肾损伤仍是患者治疗过程中的一个障碍。细胞外信号调节蛋白激酶1/2(ERK)是CP诱导肾毒性的关键参与者,被认为参与了线粒体自噬、自噬和细胞凋亡的调节。使用人肾近端小管细胞(HK-2)和BALB/cN小鼠来确定ERK在CP诱导的急性肾损伤中的作用。我们发现,活性ERK在凋亡事件中参与细胞活力降低,但在治疗早期发挥保护作用。ERK的激活作为线粒体数量的维持者,参与线粒体自噬的起始,但在其传导中无显著作用。在CP治疗后期,当ATP被剥夺时,除了激活细胞凋亡外,还会启动需要ERK激活的一般自噬作为反应。此外,ERK的激活导致储备呼吸能力下降,并在CP治疗期间控制糖酵解调节。此外,我们发现ERK激活也是诱导NOXA基因和蛋白表达以及FoxO3a核转位所必需的,但不是常规ERK诱导的FoxO3a在Ser294位点的磷酸化所必需的。总之,本研究详细深入地了解了ERK激活在CP诱导的肾损伤不同时间点的参与情况及其对关键细胞过程的影响。包括米哚妥林在内的ERK激活抑制剂在为接受CP化疗的患者开发治疗急性肾损伤的新治疗策略中具有重要意义。